Cannabis clinical research, mapped to the human body.
A continuously updated index of peer-reviewed studies on medicinal cannabis and cannabinoids — sourced from PubMed, summarised in plain English, and organised by the body system they affect. Pick a tile to filter, or search the full library below.
This is a randomized, controlled clinical trial investigating the therapeutic potential of cannabinoids for treating veterans who suffer from Post Traumatic Stress Disorder (PTSD) and suicidal ideation. The study aims to evaluate the effects of cannabis on mental health conditions in a military veteran population. This trial is currently recruiting participants.
This study is investigating whether neuroimaging of brain activity related to learning can predict treatment response in adolescents aged 14-17 for cannabis use disorder. Participants will undergo a brain scan, followed by 10 weekly virtual sessions involving self-reporting and drug tests, with incentives for abstinence. The trial is currently recruiting.
This registered trial is investigating whether transcranial direct current stimulation (tDCS) can help reduce cannabis use in 110 patients with co-occurring schizophrenia and cannabis use disorder. The study aims to measure changes in cannabis consumption, craving, addiction severity, schizophrenia symptoms, and overall functioning.
This registered clinical trial is recruiting patients with cancer to evaluate the safety, tolerability, and efficacy of daily oral cannabis over approximately 4 months. The study aims to assess whether cannabis can alleviate cancer and cancer treatment side effects, including pain, nausea, vomiting, appetite, sleep, and overall quality of life. Participants will be randomized to receive either an active cannabis dose or a placebo.
This is an ongoing outpatient clinical trial investigating how repeated administration of cannabidiol (CBD) influences the behavioral effects and pain-relieving properties of cannabis in healthy human volunteers. The study aims to understand CBD's role in moderating cannabis outcomes and abuse liability.
This is an ongoing longitudinal study recruiting medical cannabis users with chronic pain to assess the impact of cannabis use on cognition, neural function, and drug exposure. It will compare outcomes between CBD-dominant and THC-dominant products, evaluating changes in executive functions, learning, memory, white matter microstructure, and functional brain activity over four months. The study is currently recruiting participants.
This ongoing study is investigating the impact of cannabis use on brain function in adolescents who also experience depression. It aims to understand the neural and psychiatric consequences of cannabis consumption in this vulnerable population.
This registered trial aims to investigate the impact of acute exercise on cognitive functions and blood markers of brain plasticity in regular chronic cannabis users compared to non-users. The study will assess how the endocannabinoid system responds to exercise, given that chronic cannabis use alters ECS activity. It seeks to understand if exercise-induced increases in endocannabinoids contribute to neurogenesis and other beneficial adaptations.
This registered clinical trial is investigating whether a combined intervention can help young adults who experience problems with alcohol and cannabis use, as well as sleep difficulties, to reduce these issues. The study aims to recruit 800 participants to evaluate the effectiveness of this intervention.
This registered trial is investigating the effect of medical marijuana use, potentially combined with prescription opioid use, on the driving performance of adults aged 50 and older who experience chronic or severe non-malignant pain. It aims to systematically assess driving ability in this demographic, an area currently lacking robust research. The study also seeks to understand how older adults self-regulate their medication use and driving behavior.
This registered clinical trial aims to investigate the genetic factors influencing vulnerability to cannabis use disorder (CanUD) and psychosis, as well as individual responses to cannabinoids and treatments for CanUD. It focuses on understanding the complex genetic relationship between cannabis exposure, CanUD, and schizophrenia. The study is currently recruiting participants to explore these genetic influences.
This registered trial is investigating carcinogen and toxicant exposure in young adults who use both e-cigarettes and cannabis. The study will measure nicotine, cannabis, and toxicant levels in blood and urine, alongside assessing user behaviors. The goal is to understand the impact of co-using these products in this population.
This registered clinical trial aims to investigate the effects of hemp-derived CBD+THC, hemp-derived CBD-THC, or placebo in older adults (over 65) who use cannabis for pain, anxiety, or mood problems. The study seeks to provide data on harm reduction strategies for this growing demographic of cannabis users. It is an 8-week randomized controlled trial.
This is an ongoing Phase 2 clinical trial, MIVetsCan Can-Coach, designed to evaluate the effectiveness of four coaching sessions in assisting Veterans with chronic pain to better utilize their self-selected cannabis products for pain management and associated symptoms. The study is currently recruiting participants.
This is a registered, ongoing, randomized controlled trial investigating whether plant-derived cannabidiol (CBD) can reduce cannabis concentrate use, subjective effects of cannabis, or cannabis cravings in regular cannabis concentrate users who are not seeking to quit. Participants will receive either 200mg/400mg of CBD or a placebo daily for four weeks.
This registered trial aims to investigate the potential harm-reducing effects of hemp-derived CBD in young adult cannabis users. Participants will be randomized to receive CBD or placebo, with a focus on their regular cannabis use patterns in a naturalistic setting.
This is an ongoing clinical trial investigating the effects of cannabidiol (CBD) in patients with end-stage metastatic castration-resistant prostate cancer (mCRPC). The primary goal is to see if CBD can reduce opioid use for pain, while also assessing its impact on pain levels, quality of life, physical activity, inflammation, and potential anti-tumor properties. Participants will receive either CBD or a placebo for nine weeks.
This registered trial aims to assess the preliminary effectiveness of daily oral cannabis in promoting weight loss among obese individuals. The study is currently recruiting participants to evaluate this intervention.
This registered randomized crossover trial will investigate how 36 regular cannabis consumers self-titrate their THC dose when vaping high-potency cannabis concentrates. It aims to compare subjective, cognitive, physiological, and pharmacokinetic effects across different THC potencies (30%, 60%, 90%) and explore potential sex differences. The study seeks to provide evidence on acute harms associated with concentrates to inform policy decisions regarding their regulation and public health messaging.
cannabis use disorderpsychotic disorderscognitive impairment
This registered clinical trial is investigating whether hemp-derived cannabidiol (CBD), with or without Delta-9-tetrahydrocannabinol (THC), can help reduce cannabis use and symptoms of cannabis use disorder (CUD) in adults. Participants receive either full-spectrum CBD, broad-spectrum CBD, or a placebo, alongside psychotherapy, over an 8-week period with follow-ups.
This registered clinical trial is investigating the feasibility, acceptability, and preliminary efficacy of a digital intervention designed to address co-occurring cannabis use disorder and depression. Participants will be randomized to either a specific digital intervention (AMP-C) or symptom tracking, with outcomes measuring changes in depressive symptoms and cannabis use, alongside usability ratings. The study is currently recruiting participants to assess this novel digital therapeutic approach.
DepressionMajor Depressive DisorderCannabis Use Disorder
This study aims to determine if pregnenolone can reverse acute cannabis intoxication and its associated symptoms in healthy adults. It is a placebo-controlled, within-subject crossover study currently recruiting participants. The goal is to lay the groundwork for future research into CB1-receptor NAM medications and validate pregnenolone as a treatment.
This registered trial aims to investigate the effects of two types of repetitive transcranial magnetic stimulation (rTMS) on cannabis craving and brain connectivity in individuals with schizophrenia/schizoaffective disorder and healthy cannabis users. It hypothesizes that different brain circuits are involved in cannabis use in these populations. The study seeks to identify brain targets for future treatments to reduce craving and improve cognitive performance.
Cannabis Use DisorderSchizophreniaSchizoaffective Disorder
This study aims to investigate how cannabis-based products affect physiological arousal in healthy volunteers who are experiencing anxiety due to sleep deprivation. It seeks to understand the body's response to these products under such conditions. The study is currently recruiting participants.
This registered clinical trial aims to explore how acute THC administration affects reward processing differently in men and women with cannabis use disorder. Researchers will use neuroimaging to examine brain changes related to reward anticipation after participants receive either THC or a placebo. The study seeks to understand sex-specific neurobehavioral responses to THC.
This registered clinical trial aims to explore how acute cannabis exposure affects men and women differently. Researchers hope to identify the underlying biological mechanisms behind any observed gender-specific responses. The study is currently recruiting participants.
This study is investigating the effects of cannabidiol (CBD) and tetrahydrocannabinol (THC) on the microbiome and neuroinflammation in individuals with HIV. It aims to understand how cannabis use and HIV interact to affect the brain and inflammation markers. The study is currently recruiting and involves different treatment sequences over six weeks, including physical exams and blood tests.
This study aims to understand the relationship between tobacco/nicotine and cannabis use in young adults aged 18-25 during a tobacco/nicotine quit attempt. Participants will receive 12 weeks of tobacco/nicotine cessation treatment. The research will use behavioral economics principles to explore co-use dynamics, with all procedures conducted remotely.
This feasibility study investigates a virtual, group-based emotional therapy (vEAET-H) for Israeli adults with chronic musculoskeletal pain who are also using medical cannabis. The trial aims to assess the therapy's feasibility and its potential to reduce pain and improve emotional well-being. Participants will attend 8 weekly virtual sessions, completing questionnaires on various health outcomes.
This registered clinical trial aims to compare the effects of THC and CBD oils on cognition and bladder symptoms in individuals with Multiple Sclerosis. Participants will be randomly assigned to receive either CBD or THC for 15 weeks, completing questionnaires and cognitive tests.